Translate 
Abstract
A 25-year-old man presented with a locally advanced lacrimal gland adenocarcinoma with parotid metastasis. The lesion was strongly HER-2 positive (3+) on immunohistochemistry. The patient was treated with neoadjuvant trastuzumab emtansine, an antibody-drug conjugate targeting HER-2. The patient had an excellent response to neoadjuvant therapy trastuzumab emtansine, with a significant decrease in the size of the lacrimal gland carcinoma, making eye-sparing surgery a viable option for the patient. Furthermore, there was nearly complete resolution of the parotid metastasis; thus, radical neck dissection and parotidectomy were avoided.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
